New Zealand shares rose, led by Pacific Edge after it was granted a US patent for skin cancer detection, signalling a new product line for the biotech company.
Chorus fell after the Commerce Commission said it had been advised a variant 'Boost' service would breach the terms of the company's regulation.
The NZX 50 Index rose 4.153 points, or 0.1 percent, to 5228.549. Within the index stocks were mixed, as 18 gained, 20 fell and 12 were unchanged. Turnover was $156 million.
Pacific Edge jumped 9.8 percent to 90 cents, and has gained 20 percent in the past month. The Dunedin-based biotech company is targeting the US market with its non-invasive bladder cancer test by securing healthcare provider trials, and announced it had secured a US patent for a skin cancer test today. Earlier in the year the stock touched a record of $1.76, before falling in a global sell-off of biotech and software stocks when investors questioned their high valuation to earnings ratio.
"There has been a string of positive announcements for the company which have a pretty strong impact on the share price," said Mark Lister, head of private wealth research at Craigs Investment Partners. "It's been a very big rebound, but it is still well and truly off those high levels."